Q/C Technologies, Inc.
As of Oct 22, 2026, Q/C Technologies is in Stage 4, the downtrend phase, now in week 14 (since Jul 17, 2026). It closed at $0.53, 92.3% below its 52-week high and below its 200-day average, which is falling.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is QCLS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
QCLS among Computer Hardware37th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | WDC | Stage 3 · wk 10 | 98 | −25.2% |
| 2 | DELL | Stage 2 · wk 30 | 98 | −17.5% |
| 3 | STX | Stage 3 · wk 1 | 98 | −30.4% |
| 4 | QMCO | Stage 2 · wk 20 | 91 | −34.6% |
| 5 | CRSR | Stage 2 · wk 21 | 91 | +0.9% |
| 6 | P | Stage 2 · wk 10 | 78 | +10.5% |
| 7 | CRCT | Stage 2 · wk 11 | 77 | +8.8% |
| 8 | UMAC | Stage 3 · wk 1 | 77 | −28.3% |
| …37 | QCLS | Stage 4 · wk 14 | 8 | −39.7% |
Q/C Technologies: quick answers
What stage is Q/C Technologies in?
As of Oct 22, 2026, Q/C Technologies (QCLS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 17, 2026 and is in week 14. What the four stages mean
Is Q/C Technologies in an uptrend?
No. Q/C Technologies is in a Stage 4 downtrend. It trades 83.4% below its 200-day average, which is falling.
How far is Q/C Technologies from its 52-week high?
Q/C Technologies closed at $0.53 on Oct 22, 2026, 92.3% below its 52-week high of $6.92. Its 52-week low is $0.44.
How has Q/C Technologies performed over the past year?
As of Oct 22, 2026, Q/C Technologies is down 87.3% over the past year and down 87.5% so far in 2026.
Which sector and industry is Q/C Technologies in?
Q/C Technologies is in the Computer Hardware industry, part of the Information Technology sector.
About this companyInformation Technology· Computer Hardware
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.